TAX 323 Trial – Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

👉TAX 323 Jan B. Vermorken, M.D et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

👉Background

  • Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF):
    • Improves outcomes in squamous cell carcinoma of the head and neck.
  • In the TAX 323 they compared:
    • TPF with PF as induction chemotherapy in patients with locoregionally advanced, unresectable disease.

👉Methods

  • The TAX 323 randomly assigned eligible patients between the ages of 18 and 70 years who had stage III or stage IV disease and no distant metastases to:
    • Receive either TPF (docetaxel and cisplatin, day 1; fluorouracil by continuous infusion, days 1 to 5) or PF every 3 weeks for four cycles.
  • Patients without progression of disease:
    • Received radiotherapy within 4 to 7 weeks after completing chemotherapy.
  • The primary end point was progression free survival.

👉Results

  • A total of 358 patients underwent randomization:
    • With 177 assigned to the TPF group and 181 to the PF group.
  • At a median follow-up of 32.5 months.
  • The median progression-free survival was:
    • 11.0 months in the TPF group
    • 8.2 months in the PF group
      • Hazard ratio for disease progression or death in the TPF group:
        • 0.72; P=0.007.
  • Treatment with TPF resulted in a reduction in the risk of death:
    • Of 27% (P=0.02).
  • With a median overall survival of:
    • 18.8 months in the TPF, as compared with 14.5 months in the PF group.
  • There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group.
  • More grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group.
  • The rates of death from toxic effects were:
    • 2.3% in the TPF group and 5.5% in the PF group.

👉Conclusions

  • As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel:
    • Significantly improved progression- free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck:
      • ClinicalTrials.gov number, NCT00003888.

#Arrangoiz #Surgeon #CancerSurgeon #HeadandNeckSurgeon #SurgicalOncologist #HeadandNeckCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s